Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Phase 1 Completed 32 enrolled Daiichi Sankyo

NaSingle-groupOpen-labelTreatment

Summary

An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.

Timeline

Start: 2006-11
Primary completion: 2010-02
Completion: 2010-02

Publications

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	efatutazone	Small molecule	0.1 mg	Oral
Subject	efatutazone	Small molecule	0.25 mg	Oral
Subject	efatutazone	Small molecule	1.15 mg	Oral

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Summary

Timeline

Publications

Drugs

Indications